Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

1.3K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.3K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

353
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
353
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

300
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
300
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

178
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
178
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

157
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
157
Cardiopulmonary Resuscitation I: Adult01:21

Cardiopulmonary Resuscitation I: Adult

411
Cardiopulmonary resuscitation, or CPR, is a life-saving emergency procedure performed when a person's heart has stopped beating or they are no longer breathing. The foundation of CPR is Basic Life Support (BLS), which focuses on the early recognition of cardiac arrest, the immediate start of high-quality chest compressions, and the timely use of an automated external defibrillator (AED).Assessing Responsiveness and Checking the Carotid PulseWhen approaching an unresponsive person, first ensure...
411

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

60 years of ARDS and the evolution of extracorporeal lung support - from ECMO to ECCO<sub>2</sub>R.

Intensive care medicine·2026
Same author

ECMO for patients with obesity: evidence and practice.

Intensive care medicine·2026
Same author

How to optimize brain perfusion and prevent cerebral complications during extracorporeal life support.

Intensive care medicine·2026
Same author

Palliative and End-of-Life Care Utilization in Cardiogenic Shock Complicating Acute Myocardial Infarction: A Population-Based Study.

JACC. Advances·2026
Same author

Long-term quality of life and functional outcomes in extracorporeal membrane oxygenation survivors.

JHLT open·2026
Same author

Visual Right Ventricular Assessment in ICU: A Multicenter International Study.

Critical care medicine·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Dec 14, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.5K

Apoyo circulatorio temporal para el choque cardiogénico

Alain Combes1, Susanna Price2, Arthur S Slutsky3

  • 1Sorbonne Université, Institute of Cardiometabolism and Nutrition, Paris, France; Service de Médecine Intensive-Réanimation, Höpitaux Universitaires Pitié Salpêtrière, Assistance Publique-Höpitaux de Paris, Institut de Cardiologie, Paris, France.

Lancet (London, England)
|July 20, 2020
PubMed
Resumen

Los sistemas de apoyo circulatorio temporal ofrecen una alternativa a los vasopresores e inotrópicos para el manejo del choque cardiogénico. Esta revisión examina su base fisiológica, evidencia y consideraciones éticas.

Más Videos Relacionados

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.9K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

23.8K

Videos de Experimentos Relacionados

Last Updated: Dec 14, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.5K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.9K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

23.8K

Área de la Ciencia:

  • Cardiología
  • Medicina cardiovascular
  • Dispositivos médicos

Sus antecedentes:

  • El shock cardiogénico surge de eventos cardíacos agudos o enfermedad cardíaca avanzada.
  • Los tratamientos actuales como los vasopresores y los inotrópicos tienen limitaciones, incluida una mayor demanda de oxígeno en el miocardio y una alteración de la perfusión.
  • Los sistemas mecánicos de apoyo circulatorio temporal se utilizan cada vez más a pesar de los costos y las brechas de evidencia.

Objetivo del estudio:

  • Revisar la base fisiológica del apoyo circulatorio temporal en el choque cardiogénico.
  • Evaluar la evidencia de las indicaciones y contraindicaciones de estos productos.
  • Discutir las consideraciones éticas y las necesidades futuras de la investigación.

Principales métodos:

  • Revisión de la literatura sobre los sistemas de apoyo circulatorio temporal para el shock cardiogénico.
  • Análisis de los principios fisiológicos y pruebas clínicas.
  • Examen de las implicaciones éticas y de las lagunas en la investigación.

Principales resultados:

  • El apoyo circulatorio temporal aumenta el rendimiento cardíaco, ofreciendo una alternativa a los agentes farmacológicos.
  • Las pruebas que apoyan las indicaciones y contraindicaciones específicas siguen siendo limitadas.
  • Existen consideraciones éticas importantes y una necesidad de investigación de alta calidad.

Conclusiones:

  • El apoyo circulatorio temporal es una opción creciente pero compleja para el shock cardiogénico.
  • La investigación adicional es crucial para establecer el uso óptimo, la eficacia y la seguridad.
  • Equilibrar beneficios, riesgos y preocupaciones éticas es primordial en la toma de decisiones clínicas.